Jeffrey E. Lancet

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Targeting BET Proteins downregulates miR-33a to promote synergy with PIM inhibitors in CMML”.

Targeting BET Proteins downregulates miR-33a to promote synergy with PIM inhibitors in CMML

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.11.01.514753

N/A

0DataRank · unranked

0 citations

Maria E. Balasis, Hannah Newman, Moritz Binder, Alexis Vedder, Fumi Kinose +19 more

Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies

Cancer Chemotherapy and Pharmacology(2023)10.1007/s00280-023-04511-0

N/A

0DataRank · unranked

20 citations

Amanda Kagan, Michelle A. Rudek, Maciej Kmieciak, Mary Beth Tombes, Ellen Shrader +7 more

Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3929

N/A

0DataRank · unranked

5 citations

Maria E. Balasis, Hannah Newman, Moritz Binder, Alexis Vedder, Fumi Kinose +20 more